Press Releases

8/2/2019
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor

7/29/2015
Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

5/7/2015
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

12/11/2014
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer

PR Contact

Susan Kinkead
Kinkead Communications
415.509.3610
susan@kinkeadcomm.com

Press Kit

Plexxikon’s corporate materials, including corporate logo, executive bios and photos.